05.03.2024
The Clinical and Diagnostic Department of Hematology and Hemostasis Disorders of the NMRC for Hematology of the Ministry of Health of the Russian Federation is conducting a clinical trial of the ANB-002-1/ SAFRAN gene therapy drug in patients with severe hemophilia B. The drug was developed by the Russian biotechnology company BIOCAD.
The drug is administered by a single long-term intravenous infusion. It is assumed that the studied gene therapy drug will be administered once.
In the world of science, the development of gene therapy began in the 1980s. The first gene therapy drug for the treatment of hemophilia was registered in Europe in August 2022.
